Arvinas (NASDAQ:ARVN) Rating Increased to Hold at Wall Street Zen

Arvinas (NASDAQ:ARVN - Get Free Report) was upgraded by stock analysts at Wall Street Zen from a "sell" rating to a "hold" rating in a report released on Saturday.

ARVN has been the subject of several other reports. Wells Fargo & Company reaffirmed an "equal weight" rating and issued a $11.00 target price (down from $15.00) on shares of Arvinas in a research report on Tuesday. BTIG Research reissued a "buy" rating and issued a $18.00 price target on shares of Arvinas in a research note on Tuesday. Stephens restated an "overweight" rating and issued a $18.00 target price on shares of Arvinas in a research note on Wednesday, June 3rd. Weiss Ratings lowered Arvinas from a "sell (d-)" rating to a "sell (e+)" rating in a research report on Thursday, July 30th. Finally, Citigroup lifted their price target on Arvinas from $21.00 to $24.00 and gave the company a "buy" rating in a research report on Monday, May 4th. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, three have issued a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, Arvinas presently has an average rating of "Hold" and a consensus target price of $14.90.

Arvinas Stock Performance

ARVN opened at $8.75 on Friday. The stock has a market capitalization of $564.55 million, a PE ratio of 87.51 and a beta of 1.71. The stock's 50 day moving average price is $8.05 and its 200-day moving average price is $10.24. Arvinas has a 52-week low of $6.09 and a 52-week high of $14.51.

Arvinas (NASDAQ:ARVN - Get Free Report) last announced its quarterly earnings results on Tuesday, August 4th. The company reported $2.58 EPS for the quarter, topping analysts' consensus estimates of ($0.37) by $2.95. The company had revenue of $249.70 million during the quarter, compared to analyst estimates of $60.71 million. Arvinas had a return on equity of 1.91% and a net margin of 2.94%.The firm's revenue was up 1014.7% on a year-over-year basis. During the same quarter last year, the firm posted ($0.84) earnings per share. Research analysts forecast that Arvinas will post -1.15 EPS for the current fiscal year.

Insider Activity at Arvinas

In related news, CFO Andrew Saik sold 11,139 shares of the business's stock in a transaction dated Monday, May 11th. The shares were sold at an average price of $9.94, for a total transaction of $110,721.66. Following the sale, the chief financial officer owned 193,128 shares of the company's stock, valued at $1,919,692.32. The trade was a 5.45% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Randy Teel sold 9,657 shares of the company's stock in a transaction dated Monday, May 11th. The stock was sold at an average price of $9.94, for a total transaction of $95,990.58. Following the completion of the sale, the chief executive officer owned 287,218 shares in the company, valued at approximately $2,854,946.92. This trade represents a 3.25% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 41,728 shares of company stock valued at $402,649 in the last three months. Company insiders own 7.30% of the company's stock.

Institutional Trading of Arvinas

Hedge funds and other institutional investors have recently made changes to their positions in the stock. BlackRock Inc. purchased a new stake in shares of Arvinas in the second quarter worth $63,232,000. TCG Crossover Management LLC bought a new position in shares of Arvinas during the third quarter valued at $13,780,000. Balyasny Asset Management L.P. raised its position in shares of Arvinas by 469.1% in the 3rd quarter. Balyasny Asset Management L.P. now owns 1,207,267 shares of the company's stock worth $10,286,000 after purchasing an additional 995,125 shares during the last quarter. Qube Research & Technologies Ltd raised its position in shares of Arvinas by 154.8% in the 3rd quarter. Qube Research & Technologies Ltd now owns 1,486,864 shares of the company's stock worth $12,668,000 after purchasing an additional 903,337 shares during the last quarter. Finally, Millennium Management LLC boosted its stake in Arvinas by 208.4% in the 1st quarter. Millennium Management LLC now owns 1,310,326 shares of the company's stock worth $9,198,000 after purchasing an additional 885,483 shares in the last quarter. Hedge funds and other institutional investors own 95.19% of the company's stock.

Key Arvinas News

Here are the key news stories impacting Arvinas this week:

• Positive Sentiment: Zacks upgraded Arvinas to “Strong Buy.” The firm’s Zacks Rank #1 reflects improving expectations for the company’s earnings outlook and could support further buying interest. Arvinas Upgraded to Strong Buy
• Positive Sentiment: Arvinas reported a major quarterly earnings and revenue beat. Adjusted earnings were $2.58 per share versus the consensus estimate of a $0.37 loss, while revenue reached $249.7 million compared with expectations of $60.7 million. The sharp year-over-year revenue increase provides a fundamental reason for the recent rise in the shares. Arvinas Trading Higher on Strong Earnings
• Positive Sentiment: HC Wainwright raised several longer-term EPS estimates. The firm improved its forecasts for fiscal 2026 through 2029 and moved its fiscal 2030 outlook to a profit of $0.07 per share from a projected loss, suggesting better long-term operating prospects.
• Neutral Sentiment: Analyst opinions remain divided. BTIG maintained a Buy rating, while Wells Fargo lowered its rating to Equal Weight, limiting the impact of the bullish Zacks call. Arvinas Earns Buy Rating from BTIG Arvinas Rating Lowered to Equal Weight
• Negative Sentiment: HC Wainwright cut its near-term earnings forecasts. Q3 2026 EPS was reduced to a loss of $1.20 from $1.02, and Q4 EPS to a loss of $1.19 from $1.02. The revisions reinforce expectations for continued losses and may weigh on the stock.
• Negative Sentiment: A recent analyst downgrade pressured the shares. The downgrade adds caution after the earnings-driven advance, particularly given Arvinas’ projected full-year loss and its position below the 200-day moving average. Arvinas Shares Down on Analyst Downgrade

About Arvinas

Arvinas, Inc NASDAQ: ARVN is a biopharmaceutical company focused on the development of therapies based on targeted protein degradation. Utilizing its proprietary proteolysis-targeting chimera (PROTAC®) platform, Arvinas aims to selectively eliminate disease-causing proteins rather than merely inhibit their activity. This novel approach has the potential to address a range of diseases, including oncology, neurodegeneration and inflammation, by harnessing the body's natural protein-recycling systems.

The company's most advanced clinical candidates address hormone-driven cancers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source